ABI-009, nab-Sirolimus, an mTOR Inhibitor with High Lung Accumulation in Preclinical Models: Initial Results from an Ongoing Phase I/II Safety and Preliminary Efficacy Study in Severe PAH

Home ABI-009, nab-Sirolimus, an mTOR Inhibitor with High Lung Accumulation in Preclinical Models: Initial Results from an Ongoing Phase I/II Safety and Preliminary Efficacy Study in Severe PAH

ABI-009, nab-Sirolimus, an mTOR Inhibitor with High Lung Accumulation in Preclinical Models: Initial Results from an Ongoing Phase I/II Safety and Preliminary Efficacy Study in Severe PAH

/ Publications

Share the Post

About the Author

Related Posts

Patients With Severe Pulmonary Arterial Hypertension Treated With ABI-009, nab-Sirolimus, an mTOR Inhibitor: Interim Results From a Phase 1 Clinical Trial
Aadi Bioscience Receives Breakthrough Therapy Designation for ABI-009 in PEComa Indication
Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services
Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowen’s 42nd Annual Health Care Conference
Aadi Reports Third Quarter 2021 Financial Results and Provides Business Update
Read More
Behzad Aghazadeh, PhD
Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022
nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer: A Phase 2, Open-Label, Single-Arm, Prospective, Multicenter Study

Comments

Comments are closed.